Cellectis (NASDAQ:CLLS) Stock Price Crosses Above Fifty Day Moving Average of $2.09

Cellectis S.A. (NASDAQ:CLLS)’s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.09 and traded as high as $2.10. Cellectis shares last traded at $2.10, with a volume of 8,386 shares trading hands.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Oppenheimer decreased their target price on Cellectis from $11.00 to $10.00 and set an “outperform” rating for the company in a research report on Wednesday, June 12th. JMP Securities reiterated a “market outperform” rating and set a $6.00 price target on shares of Cellectis in a research note on Friday, May 31st. Finally, StockNews.com assumed coverage on Cellectis in a research note on Saturday. They set a “sell” rating for the company.

Cellectis Trading Up 1.7 %

The firm has a 50 day simple moving average of $2.08 and a 200 day simple moving average of $2.52. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.63 and a current ratio of 1.63. The firm has a market cap of $115.89 million, a P/E ratio of -1.62 and a beta of 3.10.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share for the quarter. Cellectis had a negative net margin of 529.81% and a negative return on equity of 67.41%. The business had revenue of $6.50 million during the quarter. On average, equities research analysts predict that Cellectis S.A. will post -0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

A number of large investors have recently modified their holdings of the company. Baillie Gifford & Co. raised its holdings in shares of Cellectis by 1.3% during the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after buying an additional 10,605 shares in the last quarter. Principal Financial Group Inc. increased its stake in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares during the period. XTX Topco Ltd purchased a new position in Cellectis in the 2nd quarter worth approximately $29,000. Finally, Long Focus Capital Management LLC increased its stake in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the period. 63.90% of the stock is owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.